CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July

CMS is delaying the effective date of a rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing models.

The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP)

Read More »

As Contract Pharmacy Losses Climb into the Billions, Fine for Overcharging 340B Providers Gets Closer to $6,000 Per Instance Mark

HHS OIG has raised the civil monetary penalty for overcharging a 340B covered entity to adjust for inflation.

The federal fine for overcharging a 340B covered entity just went up from $5,883.00 to $5,953.00 per each instance of overcharging.

Please Login or Become a Paid Subscriber to View this Content

Read More »

In Pursuit of New 340B Leader, HRSA Expands Its Search Beyond Pharmacists

In a major shift, HRSA has dropped its requirement that the Director of the Office of Pharmacy Affairs (OPA) must have a pharmacy degree and be a licensed pharmacist.

In a major organizational change, the U.S. Health Resources and Services Administration (HRSA) has redefined the job of Director of the Office of Pharmacy Affairs (OPA), the HRSA unit that runs the 340B program.

Please Login

Read More »

News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement

CMS in 2022 will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for many hospitals’ 340B-purchased drugs and biologicals.

In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’

Read More »

CMS Decision on Whether to Keep Part B Drug Payment Cuts for 340B Hospitals Could Come as Soon as Today

CMS could disclose as soon as today whether it will continue, end, or modify its nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

The U.S. Centers for Medicare & Medicaid Services (CMS) could disclose as soon as today whether it will continue, end, or modify the nearly 30% cut in certain hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

Read More »

Biden Administration Wants to Scuttle Azar’s Rule to Automatically Snuff Out HHS Regulations

The Biden administration says it wants to withdraw or repeal ex-HHS Secretary Alex Azar’s final rule that will automatically extinguish all HHS regulations if HHS does not renew each regulation within a certain timeframe. | C-SPAN

The Biden administration last Friday, as widely expected, proposed withdrawing or repealing a Trump administration final rule that will automatically extinguish all U.S. Health and Human Services (HHS) regulations if HHS does not renew each regulation within a certain timeframe.

Read More »

HRSA Orders Two Drug Makers to Repay 340B Entities After Audits Show Overcharges

HRSA has ordered Akorn Inc. and BioComp Pharma to repay 340B covered entities for overcharges following audits.

The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Updates on 340B Administrative Dispute Resolution Lawsuits and ADR Panel Hearings

There were several recent important developments involving HRSA's 340B administrative dispute resolution system. | Credit: "File:Massimo Busacca, Referee, Switzerland (10).jpg" by Steindy (talk) 11:44, 19 June 2011 (UTC) is licensed under CC BY-SA 3.0

The federal government and the two groups that sued it separately to force it to issue long delayed 340B administrative dispute resolution (ADR) regulations agreed last night to keep stays in place in both lawsuits until Jan. 3, 2022. Meanwhile,

Read More »

California Still Plans to Move Medicaid Pharmacy Benefits to Fee-for-Service in January

California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year.

California’s Medicaid (Medi-Cal) program remains on track to move its pharmacy benefit from managed care to fee-for-service early next year, a change that would deprive federally qualified health centers and other safety net health care providers of hundreds of millions

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report